EPA Science Inventory

A Public-Private Consortium Advances Cardiac Safety Evaluation: Achievements of the HESI Cardiac Safety Technical Committee

Citation:

Pierson, J., B. Berridge, M. Brooks, K. Dreher, J. Koerner, A. Schultze, R. Sarazan, J. Valentin, H. Vargas, AND S. Pettit. A Public-Private Consortium Advances Cardiac Safety Evaluation: Achievements of the HESI Cardiac Safety Technical Committee. JOURNAL OF PHARMACOLOGICAL & TOXICOLOGICAL METHODS. Elsevier Science Ltd, New York, NY, 68(1):7-12, (2013).

Description:

The evaluation of cardiovascular side-effects is a critical element in the development of all new drugs and chemicals. Cardiac safety issues have been and continue to be a major cause of attrition and withdrawal due to Adverse Drug Reactions (ADRs) in pharmaceutical drug development. The HESI Technical Committee on Cardiac Safety, an international consortium of academic, government, and industry scientists, provides a unique opportunity to share resources and expertise to improve cardiovascular safety evaluation for new drugs and chemicals. This article describes the evolution of the HESI Cardiac Safety Technical Committee from 2000-2013 and the positive impacts resulting from this collaboration.

Purpose/Objective:

Identifies and highlights commonality for health risk assessment needs between safe drugs AND chemical safety risk assessment as well as the use of stem cell technologies to assess both drug and chemical safety for regulatory decisions

URLs/Downloads:

PIERSON ET AL J PHARMACOL TOXICOL METH 2013 ABSTRACT AND CITATION.PDF   (PDF,NA pp, 15.753 KB,  about PDF)

Record Details:

Record Type: DOCUMENT (JOURNAL/PEER REVIEWED JOURNAL)
Start Date: 04/04/2014
Completion Date: 04/04/2014
Record Last Revised: 05/20/2014
Record Created: 04/04/2014
Record Released: 04/04/2014
OMB Category: Other
Record ID: 272608

Organization:

U.S. ENVIRONMENTAL PROTECTION AGENCY

OFFICE OF RESEARCH AND DEVELOPMENT

NATIONAL HEALTH AND ENVIRONMENTAL EFFECTS RESEARCH LAB

ENVIRONMENTAL PUBLIC HEALTH DIVISION

CARDIOPULMONARY AND IMMUNOTOXICOLOGY BRANCH